Cholestenone

Cholestenone (4-cholesten-3-one) is an orally available antimicrobial agent that is metabolized primarily in the liver as an intermediate oxidation product of cholesterol. Cholestenone inhibits human dermal fibroblast migration and fights Helicobacter pylori infection in vitro and in mouse models by inhibiting cholesterol-α-D-glucopyranoside (CGL). Cholestenone also alleviates metabolic disorders caused by obesity in db/db mice^[1][2][3][4]. In Vitro:Cholestenone (4.7-150μM, 4 days) inhibits the growth of Helicobacter pylori in a dose-dependent manner^[1].
Cholestenone (150 μM, 2 days) inhibits the expression of CGL in Helicobacter pylori^[1].
Cholestenone affects the ordering ability of the remaining cholesterol, increases N-palmitoyl-sphingomyelin (PSM) in a short period of time, and increases the turnover rate of cholesterol after replacing 25% of cholesterol^[2].
Cholestenone (treated with 10U/mL coase for 1 hour; treated with 0.5mM MBDC for 5 minutes) inhibits the migration of human dermal fibroblasts. In Vivo:Cholestenone (oral, 0.5% wt/wt, 4 weeks) inhibits Helicobacter pylori in mice^[1].
Cholestenone (oral; 1 g, once every eight hours, 17 consecutive days for dog; 1% cholestenone, 10 and 16 days for chicken) reduces plasma cholesterol levels in dogs and chickens, but does not reduce total cholesterol levels^[3].
Cholestenone (oral, 0.25% cholestenone, 4 weeks) can alleviate obesity-related metabolic disorders in db/db mice^[4].